{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:55:45Z","timestamp":1794272145842,"version":"4.9.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>Acute ischemic stroke is a consequence of disrupted blood flow to the brain, caused by thrombosis\u2014the pathological formation of occlusive clots within blood vessels, which can embolize distally to downstream tissues and microvasculature. The highest priority of stroke treatment is the rapid removal of occlusive clots and restoration of tissue perfusion. Intravenous thrombolysis is the pharmacological standard-of-care for the dissolution of blood clots, wherein thrombolytic drugs are administered to restore vessel patency. While the introduction of recombinant tissue-plasminogen activator (rtPA) in 1996 demonstrated the benefit of acute thrombolysis for clot removal, this was countered by severe limitations in terms of patient eligibility, lytic efficacy, rethrombosis and safety implications. Development of safer and efficacious treatment strategies to improve clot lysis has not significantly progressed over many decades, due to the challenge of maintaining the necessary efficacy-safety balance for these therapies. As such, rtPA has remained the sole approved acute therapeutic for ischemic stroke for over 25 years. Attempts to improve thrombolysis with coadministration of adjunct antithrombotics has demonstrated benefit in coronary vessels, but remain contraindicated for stroke, given all currently approved antithrombotics adversely impact hemostasis, causing bleeding. This <jats:italic>Perspective<\/jats:italic> provides a brief history of stroke drug development, as well as an overview of several groups of emerging drugs which have the potential to improve thrombolytic strategies in the future. These include inhibitors of the platelet receptor glycoprotein VI and the signaling enzyme PI3-Kinase, novel anticoagulants derived from hematophagous creatures, and proteolysis-targeting chimeras.<\/jats:p>","DOI":"10.3389\/fmedt.2022.946367","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:49:40Z","timestamp":1659332980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Improving treatment for acute ischemic stroke\u2014Clot busting innovation in the pipeline"],"prefix":"10.3389","volume":"4","author":[{"given":"Joanna Shu Ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Schoenwaelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0002-9343(84)90198-0","article-title":"Successful thrombolytic therapy in two patients with renal vein thrombosis","volume":"77","author":"Rowe","year":"1984","journal-title":"Am J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/01.CIR.69.3.605","article-title":"Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology","volume":"69","author":"Van De Werf","year":"1984","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14740338.2019.1573985","article-title":"Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase","volume":"18","author":"Chester","year":"2019","journal-title":"Expert Opin Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1345\/aph.18006","article-title":"Reteplase: a new thrombolytic for the treatment of acute myocardial infarction","volume":"33","author":"Wooster","year":"1999","journal-title":"Ann Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/abr.abr_169_18","article-title":"Reteplase: structure, function, and production","volume":"8","author":"Mohammadi","year":"2019","journal-title":"Adv Biomed Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/eurheartj\/18.suppl_F.11","article-title":"Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator","volume":"18","author":"Smalling","year":"1997","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12245-021-00399-w","article-title":"Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review","volume":"15","author":"Potla","year":"2022","journal-title":"Int J Emerg Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/svn-2021-001074","article-title":"Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/svn-2015-000004","article-title":"Endovascular thrombectomy for stroke: current best practice and future goals","volume":"1","author":"Campbell","year":"2016","journal-title":"BMJ."},{"key":"B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/STR.0000000000000086","article-title":"Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke","volume":"47","author":"Demaerschalk","year":"2016","journal-title":"Stroke."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","article-title":"Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"48","author":"Yaghi","year":"2017","journal-title":"Stroke"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/neuros\/nyz042","article-title":"Epidemiology, natural history, and clinical presentation of large vessel ischemic stroke","volume":"85","author":"Rennert","year":"2019","journal-title":"Neurosurgery"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1212\/WNL.0000000000012781","article-title":"Global epidemiology of stroke and access to acute ischemic stroke interventions","volume":"97","author":"Saini","year":"2021","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/svn-2019-000262","article-title":"Acute ischaemic stroke interventions: large vessel occlusion and beyond","volume":"5","author":"Sweid","year":"2020","journal-title":"Stroke Vasc Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jama.2022.1645","article-title":"Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke","volume":"327","author":"Ren\u00fa","year":"2022","journal-title":"JAMA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1161\/STROKEAHA.114.008247","article-title":"Time-dependent thrombus resolution after tissue-type plasminogen activator in patients with stroke and mice","volume":"46","author":"Kim","year":"2015","journal-title":"Stroke."},{"key":"B21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fneur.2014.00226","article-title":"Recanalization and reperfusion therapies of acute ischemic stroke: what have we learned, what are the major research questions, and where are we headed?","volume":"5","author":"Gomis","year":"2014","journal-title":"Front Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.59.6.862","article-title":"Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator","volume":"59","author":"Alexandrov","year":"2002","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1161\/01.CIR.97.16.1632","article-title":"Thrombolysis for acute myocardial infarction","volume":"97","author":"White","year":"1998","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1468-1331.2006.01458.x","article-title":"A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke","volume":"13","author":"Mikul\u00edk","year":"2006","journal-title":"Eur J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1161\/STROKEAHA.118.024575","article-title":"Safety and outcome of intravenous thrombolysis in stroke patients on prophylactic doses of low molecular weight heparins at stroke onset","volume":"50","author":"Cooray","year":"2019","journal-title":"Stroke."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106382","DOI":"10.1016\/j.clineuro.2020.106382","article-title":"Intravenous thrombolysis for the management of acute ischemic stroke in patients therapeutically anticoagulated with heparin: a review","volume":"200","author":"Neves","year":"2021","journal-title":"Clin Neurol Neurosurg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(22)00014-9","article-title":"Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial","volume":"399","author":"van der Steen","year":"2022","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1254\/jjp.69.143","article-title":"Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model","volume":"69","author":"Kawai","year":"1995","journal-title":"Jpn J Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1055\/s-2007-996131","article-title":"Effect of the Thrombin inhibitor argatroban in acute cerebral thrombosis","volume":"23","author":"Kobayashi","year":"1997","journal-title":"Semin Thromb Hemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","article-title":"The argatroban and tissue-type plasminogen activator stroke study","volume":"43","author":"Barreto","year":"2012","journal-title":"Stroke."},{"key":"B31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/STROKEAHA.111.617902","article-title":"Adjunctive and alternative approaches to current reperfusion therapy","volume":"43","author":"Barreto","year":"2012","journal-title":"Stroke."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13231-014-0014-y","article-title":"Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke","volume":"7","author":"Tomkins","year":"2015","journal-title":"Exp Transl Stroke Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e007454","DOI":"10.1161\/JAHA.117.007454","article-title":"Combining intravenous thrombolysis and antithrombotic agents in stroke: an update","volume":"7","author":"Derex","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/STROKEAHA.111.000502","article-title":"Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome","volume":"44","author":"Kellert","year":"2013","journal-title":"Stroke."},{"key":"B35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/STROKEAHA.106.476648","article-title":"Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1161\/STROKEAHA.115.010260","article-title":"Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial","volume":"46","author":"Adeoye","year":"2015","journal-title":"Stroke."},{"key":"B37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1747493017733935","article-title":"Tenecteplase vs. alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study","volume":"13","author":"Campbell","year":"2018","journal-title":"Int J Stroke."},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood-2015-02-629717","article-title":"Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation","volume":"126","author":"Mammadova-Bach","year":"2015","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0262695","DOI":"10.1371\/journal.pone.0262695","article-title":"Platelet surface receptor glycoprotein VI-dimer is overexpressed in stroke: the Glycoprotein VI in Stroke (GYPSIE) study results","volume":"17","author":"Induruwa","year":"2022","journal-title":"PLoS ONE."},{"key":"B41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1365-2141.1995.tb08900.x","article-title":"Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency","volume":"89","author":"Arai","year":"1995","journal-title":"Br J Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2009-03-213504","article-title":"Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations","volume":"114","author":"Dumont","year":"2009","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2005.08.001","article-title":"GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism","volume":"118","author":"Lockyer","year":"2006","journal-title":"Thromb Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1055\/s-0040-1721078","article-title":"Revacept, an inhibitor of platelet adhesion in symptomatic carotid artery stenosis: design and rationale of a randomized phase II clinical trial","volume":"4","author":"Gr\u00f6schel","year":"2020","journal-title":"TH Open."},{"key":"B45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"MAbs."},{"key":"B47","first-page":"203","volume-title":"PI 3-Kinase p110","author":"Jackson","year":"2010"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood-2017-03-773614","article-title":"Integrin \u03b1IIb\u03b23 outside-in signaling","volume":"130","author":"Durrant","year":"2017","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"28648","DOI":"10.1074\/jbc.M704358200","article-title":"Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin \u03b1IIb\u03b23 adhesive function in platelets","volume":"282","author":"Schoenwaelder","year":"2007","journal-title":"J Biol Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J Thrombosis Haemostasis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1111\/j.1538-7836.2012.04912.x","article-title":"Antithrombotic phosphoinositide 3-kinase \u03b2 inhibitors in humans: a \u2018shear\u2019 delight! J Thromb Haemost","volume":"10","author":"Jackson","year":"2012"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.13027","article-title":"Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase beta inhibition and aspirin in man","volume":"13","author":"Nylander","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B53","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nchem.2744","article-title":"Tyrosine sulfation modulates activity of tick-derived thrombin inhibitors","volume":"9","author":"Thompson","year":"2017","journal-title":"Nat Chem."},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27275-8","article-title":"Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors","volume-title":"Nature Communications.","author":"Koh","year":"2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"29101","DOI":"10.1074\/jbc.M705600200","article-title":"Variegin, a |","volume":"282","author":"Koh","year":"2007","journal-title":"J Biol Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discovery."},{"key":"B57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41421-018-0079-1","article-title":"A chemical approach for global protein knockdown from mice to non-human primates","volume":"5","author":"Sun","year":"2019","journal-title":"Cell Discov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.4103\/1673-5374.308075","article-title":"Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system","volume":"16","author":"Ma","year":"2021","journal-title":"Neural Regen Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct Targeted Ther"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2022.946367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:49:44Z","timestamp":1659332984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2022.946367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":59,"alternative-id":["10.3389\/fmedt.2022.946367"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2022.946367","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"946367"}}